Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.86 -0.5%	$3.39	$1.07 ▼ $4.08	$1.02B	0.88	3.15 million shs	3.05 million shs
MGTX MeiraGTx	$8.62	$6.45	$3.85 ▼ $8.98	$692.75M	1.24	407,559 shs	400,903 shs
RLAY Relay Therapeutics	$3.50 -4.1%	$3.27	$1.78 ▼ $10.72	$625.77M	1.62	2.10 million shs	1.86 million shs
TIL Instil Bio	$26.10 -5.8%	$25.64	$9.85 ▼ $92.00	$181.68M	2.15	198,385 shs	159,263 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-0.52%	-1.78%	+8.43%	+87.38%	+173.76%
MGTX MeiraGTx	0.00%	+1.77%	+33.02%	+59.33%	+72.75%
RLAY Relay Therapeutics	-4.11%	-2.78%	+4.17%	+30.11%	-60.67%
TIL Instil Bio	-5.78%	+6.57%	-8.68%	+68.93%	+100.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	3.7101 of 5 stars	3.6	1.0	4.0	2.2	0.8	0.6
MGTX MeiraGTx	4.163 of 5 stars	3.5	1.0	4.8	2.5	2.5	0.6
RLAY Relay Therapeutics	2.406 of 5 stars	3.4	1.0	0.0	2.8	2.5	0.6
TIL Instil Bio	3.1477 of 5 stars	3.5	2.0	0.0	3.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.20	Buy	$6.75	74.87% Upside
MGTX MeiraGTx	3.00	Buy	$24.00	178.42% Upside
RLAY Relay Therapeutics	2.83	Moderate Buy	$17.67	404.76% Upside
TIL Instil Bio	3.00	Buy	$119.00	355.94% Upside

Current Analyst Ratings Breakdown

Latest TIL, RLAY, AKBA, and MGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
6/2/2025	TIL Instil Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/22/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$110.00 ➝ $105.00
5/14/2025	MGTX MeiraGTx	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $35.00
5/7/2025	RLAY Relay Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $10.00
4/28/2025	AKBA Akebia Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	AKBA Akebia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$184.91M	5.48	N/A	N/A	($0.23) per share	-16.78
MGTX MeiraGTx	$33.28M	20.81	N/A	N/A	$0.87 per share	9.91
RLAY Relay Therapeutics	$10.01M	59.95	N/A	N/A	$4.65 per share	0.75
TIL Instil Bio	N/A	N/A	N/A	N/A	$25.96 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$69.41M	-$0.21	N/A	N/A	N/A	-24.51%	N/A	-18.92%	8/6/2025 (Estimated)
MGTX MeiraGTx	-$147.79M	-$2.32	N/A	22.68	N/A	-484.90%	-241.05%	-62.93%	8/11/2025 (Estimated)
RLAY Relay Therapeutics	-$337.71M	-$2.23	N/A	N/A	N/A	N/A	-44.17%	-39.53%	8/5/2025 (Estimated)
TIL Instil Bio	-$74.14M	-$11.97	N/A	N/A	N/A	N/A	-45.52%	-29.23%	8/12/2025 (Estimated)

Latest TIL, RLAY, AKBA, and MGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AKBA Akebia Therapeutics	-$0.02	N/A	N/A	N/A	N/A	N/A
8/12/2025	N/A	TIL Instil Bio	-$1.72	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	MGTX MeiraGTx	-$0.52	N/A	N/A	N/A	$8.00 million	N/A
8/5/2025	Q2 2025	RLAY Relay Therapeutics	-$0.49	N/A	N/A	N/A	$0.07 million	N/A
5/13/2025	Q1 2025	MGTX MeiraGTx	-$0.38	-$0.51	-$0.13	-$0.51	$4.44 million	$1.93 million
5/13/2025	Q1 2025	TIL Instil Bio	-$2.02	-$4.32	-$2.30	-$4.32	N/A	N/A
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
5/5/2025	Q1 2025	RLAY Relay Therapeutics	-$0.50	-$0.46	+$0.04	-$0.46	$0.01 million	$7.68 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.89	2.23	2.02
MGTX MeiraGTx	2.34	1.53	1.51
RLAY Relay Therapeutics	N/A	19.96	19.96
TIL Instil Bio	0.58	30.33	30.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
MGTX MeiraGTx	67.48%
RLAY Relay Therapeutics	96.98%
TIL Instil Bio	60.56%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
MGTX MeiraGTx	7.50%
RLAY Relay Therapeutics	4.87%
TIL Instil Bio	47.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	262.64 million	254.76 million	Optionable
MGTX MeiraGTx	300	80.36 million	74.34 million	Optionable
RLAY Relay Therapeutics	330	171.45 million	163.10 million	Optionable
TIL Instil Bio	410	6.56 million	3.46 million	No Data

TIL, RLAY, AKBA, and MGTX Headlines

Recent News About These Companies

US FDA clears Instil Bio’s IND application for AXN-2510, a PD-L1xVEGF bispecific antibody, for a phase 1 trial in relapsed/refractory solid tumours

July 4, 2025 | pharmabiz.comP

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed ...

July 3, 2025 | manilatimes.netM

Instil Bio Announces FDA Clearance for IND of AXN-2510, Phase 1 Trial Expected by End of 2025 - Nasdaq

July 3, 2025 | nasdaq.com

Instil Bio stock jumps after FDA clearance of IND application

July 2, 2025 | in.investing.com

Instil Bio Shares Climb After FDA Clears Tumor Treatment Application

July 2, 2025 | marketwatch.com

Instil Bio Shares Surge on FDA Clearance for Investigational Cancer Therapy

July 2, 2025 | msn.com

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

July 2, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/07/02/3109003/0/en/instil-bio-announces-u-s-f-d-a-clearance-of-investigational-new-drug-ind-application-for-axn-2510-a-pd-l1xvegf-bispecific-antibody-for-a-phase-1-trial-in-relapsed-refractory-solid-.html$

Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know

June 20, 2025 | zacks.com

Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet

June 16, 2025 | zacks.com

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

June 11, 2025 | globenewswire.com

Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice

June 4, 2025 | zacks.com

Instil Bio appoints new Chief Medical Officer

June 4, 2025 | uk.investing.com

Instil Bio appoints Jamie Freedman as Chief Medical Officer

June 2, 2025 | msn.com

Instil Bio, Inc. Appoints Jamie Freedman, M.D., Ph.D., as Chief Medical Officer to Propel Cancer Therapy Development

June 2, 2025 | quiverquant.comQ

Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

June 2, 2025 | globenewswire.com

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

May 30, 2025 | globenewswire.com

Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?

May 29, 2025 | zacks.com

Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade

May 29, 2025 | zacks.com

Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success

May 25, 2025 | seekingalpha.com

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ...

May 25, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
The Boring Is Beautiful Portfolio: 3 Stocks for a Worried World
By Jeffrey Neal Johnson | June 22, 2025
View The Boring Is Beautiful Portfolio: 3 Stocks for a Worried World
Tilray Shares Blazing: What's Behind the 55% Rally This Month?
By Nathan Reiff | July 14, 2025
View Tilray Shares Blazing: What's Behind the 55% Rally This Month?
3 Stocks to Cushion Your Portfolio This Earnings Season
By Chris Markoch | July 16, 2025
View 3 Stocks to Cushion Your Portfolio This Earnings Season
Palantir’s $100M Nuclear OS Pact Boosts Bullish Case
By Chris Markoch | July 1, 2025
View Palantir’s $100M Nuclear OS Pact Boosts Bullish Case

TIL, RLAY, AKBA, and MGTX Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.86 -0.02 (-0.52%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.86 0.00 (-0.13%)

As of 07/18/2025 07:52 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

MeiraGTx NASDAQ:MGTX

$8.62 0.00 (0.00%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$8.62 0.00 (0.00%)

As of 07/18/2025 04:33 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Relay Therapeutics NASDAQ:RLAY

$3.50 -0.15 (-4.11%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.50 +0.00 (+0.14%)

As of 07/18/2025 07:47 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Instil Bio NASDAQ:TIL

$26.10 -1.60 (-5.78%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$26.78 +0.67 (+2.59%)

As of 07/18/2025 05:56 PM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time